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A growing body of experimental evidence suggests that vasodilators are elaborated during vasoconstriction and restore vasomotor tone to baseline, thereby promoting tissue perfusion and oxygenation (1, 17, 19, 37, 38) . For instance, Kanagy et al. (19) and Vo et al. (37) showed that NO, which is produced by VIP (2, 15, 32) , decreases the sensitivity of isolated rat vascular smooth muscle to vasoconstrictors, including phenylephrine, an ␣-adrenergic agonist, through cGMP-dependent and -independent mechanisms. VIP has been shown to interact with the ␣-adrenergic system and ANG II in various species (1, 3-5, 17, 23) . Mas et al. (23) showed that VIP opposes ␣-adrenoceptor stimulation of the cardiovascular system in newborn dogs. Importantly, Iwabuchi et al. (17) showed that VIP abrogates pulmonary vasoconstriction elicited by ANG II and KCl in isolated perfused rat lung, in part, by elaborating prostaglandins. In addition, ANG II has been shown to stimulate VIP release from ovine fetus adrenocortical cells in vitro and to decrease VIP catabolism in rabbits in vivo (4, 5) . Although these data suggest that ␣-adrenergic-and ANG II-dependent metabolic pathways interact with VIP, the role these interactions play in regulating vasomotor tone in vivo is uncertain.
Hence, the purpose of this study was to begin to address this issue by determining whether VIP modulates vasoconstriction elicited by phenylephrine and ANG II in vivo and, if so, to begin to elucidate the mechanisms underlying this phenomenon.
METHODS

General Methods
Preparation of animals. Adult male Golden Syrian hamsters (n ϭ 46; 132 Ϯ 6 g body wt) were anesthetized with pentobarbital sodium (6 mg/100 g body wt ip). A tracheostomy was performed to facilitate spontaneous breathing. A femoral vein was cannulated to administer supplemental pentobarbital sodium (2-4 mg · 100 g body wt Ϫ1 ·h Ϫ1 ) during the experiment. A femoral artery was cannulated to monitor and record systemic arterial pressure. Body temperature was monitored and maintained constant (37-38°C) throughout the experiment by using a heating pad.
To visualize the microcirculation of the cheek pouch, we used an established method in our laboratory (9, 30, (32) (33) (34) (35) . Briefly, the left cheek pouch was spread over a small plastic base plate, and an incision was made in the outer skin to expose the cheek pouch membrane. The avascular connective tissue layer of the membrane was removed, and a plastic chamber was positioned over the base plate and secured in place by suturing the skin around the upper chamber. This chamber was connected to a reservoir containing warmed bicarbonate buffer (37-38°C), which allowed continuous suffusion of the cheek pouch. The bicarbonate buffer was bubbled continuously with 95% N 2 -5% CO 2 (pH 7.4). The chamber was also connected via a three-way valve to an infusion pump (Sage Instruments, Boston, MA) that allowed constant administration of drugs into the suffusate.
Determination of arteriolar diameter. The cheek pouch microcirculation was visualized with a microscope (Nikon, Tokyo, Japan) coupled to a 100-W mercury light source at a magnification of ϫ40. The microscope image was projected through a low-light television camera (Panasonic TR-124 MA, Matsushita Communication Industrial, Yokohama, Japan) onto a video screen (Panasonic). The inner diameter of second-order arterioles (baseline diameter 48-60 µm) was determined during the experiment from the video display of the microscope image using a videomicrometer (model VIA 100, Boeckler Instruments, Tucson, AZ). In each animal, the same arteriolar segment was used to measure vessel diameter during the experiment.
Preparation of VIP on sterically stabilized liposomes. To prepare VIP on sterically stabilized liposomes (SSL), we used a method previously described in our laboratory (31, 32) . Briefly, egg yolk phosphatidylcholine, egg yolk phosphatidylglycerol, cholesterol, and polyethylene glycol (molecular mass 2,000) linked to distearoyl-phosphatidylethanolamine (molar ratio 5:1:3.5:0.5; phospholipid content 17 mmol) were dissolved and mixed in chloroform. The solvent was evaporated at 45°C in a rotary evaporator under vacuum overnight. The resulting lipid film was rehydrated in 250 µl of saline, vortexed, bath sonicated for 5 min, and extruded through stacked polycarbonate filters using the LiposoFast apparatus (pore size 200, 100, and 50 nm; AVESTIN, Ottawa, ON, Canada). Human VIP (0.4 mg) and trehalose (30 mg) were added to the extruded suspension, which was then frozen in an acetone-dry ice bath and lyophilized overnight at Ϫ46°C under constant pressure (Foreseen 6, Labconco, Kansas City, MO). Thereafter, the lyophilized ''cake'' was resuspended in 250 µl of deionized water. VIP associated with SSL was separated from free VIP by column chromatography (Bio-Gel A-5m, Bio-Rad Laboratories, Richmond, CA) and stored at 4°C for 15 days. The size of SSL was 246 Ϯ 29 nm, as determined by quasi-elastic light scattering (Nicomp model 270 submicron particle sizer, Pacific Scientific, Menlo Park, CA). The phospholipid concentration in SSL was determined by the Barlett inorganic phosphate assay. VIP concentration in SSL was determined by a commercially available ELISA kit (Peninsula Laboratories, Belmont, CA) after SSL was dissolved with 1% SDS. The recovery was 30% for VIP and 50% for phospholipids, resulting in 0.004 mol VIP/mol phospholipids.
Experimental Protocols
Effects of a VIP receptor antagonist on vasoconstriction. The purpose of these studies was to determine whether VIP-(10-28), a VIP receptor antagonist that abrogates VIP-induced vasodilation in the cheek pouch (32), potentiates phenylephrine-and ANG II-induced vasoconstriction. Bicarbonate buffer was suffused for 45 min (equilibration period). Then phenylephrine (0.01 µM) or ANG II (0.01 nM) was suffused on the cheek pouch for 7 min. In preliminary studies, we determined that these concentrations elicit submaximal response (see below). Forty-five minutes after suffusion of phenylephrine or ANG II was stopped and arteriolar diameter returned to baseline, VIP-(10-28) (10.0 nmol) was suffused for 30 min before and during suffusion of phenylephrine (0.01 µM) or ANG II (0.01 nM) for 7 min. In another series of experiments, VIP-(1-12) (10.0 nmol), an inactive peptide fragment of VIP (32), was used. Arteriolar diameter was determined immediately before suffusion, at every minute during suffusion of each agonist, and at 5-min intervals thereafter for the entire duration of the experiment. In preliminary studies we determined that repeated suffusions of phenylephrine and ANG II were associated with reproducible results. In addition, suffusion of VIP-(10-28) and VIP-(1-12) alone for 30 min and saline (vehicle) for the entire duration of the experiment was not associated with significant changes in arteriolar diameter. The concentrations of phenylephrine, ANG II, VIP-(10-28), and VIP-(1-12) used in these studies are based on previous and preliminary studies in our laboratory and reports in the literature (22, 25, 32, 33, 39) .
Effects of VIP on vasoconstriction. The purpose of these studies was to determine whether VIP attenuates phenylephrine-and ANG II-induced vasoconstriction and, if so, whether this response is amplified by liposomal VIP. In one series of experiments, after the equilibration period, two concentrations of phenylephrine (0.01 and 0.1 µM) or ANG II (0.01 and 0.1 nM) were suffused on the cheek pouch for 7 min each in an arbitrary order. At least 30 min elapsed between subsequent suffusions of agonists. Suffusion of higher concentrations of phenylephrine and ANG II was associated with systemic absorption, as evidenced by an increase in systemic arterial pressure. Thirty minutes after suffusion of phenylephrine or ANG II was stopped and arteriolar diameter returned to baseline, VIP (1.0 nmol) was suffused for 7 min, and then the corresponding agonist was suffused again. In another series of experiments, VIP on SSL (0.1 and 1.0 nmol) or empty SSL (1.0 nmol) rather than VIP was used. Arteriolar diameter was determined during each intervention, as outlined above. In preliminary studies, we determined that arteriolar diameter returns to baseline within 2 and 18 min after suffusion of VIP and VIP on SSL is stopped, respectively. In addition, repeated suffusions of phenylephrine (0.1 µM), ANG II (0.1 nM), VIP, and VIP on SSL (0.1 and 1.0 nmol) were associated with reproducible results. The concentrations of phenylephrine, ANG II, VIP, and VIP on SSL used in these studies are based on previous and preliminary studies in our laboratory and reports in the literature (22, 25, (32) (33) (34) (35) (36) 39) .
Duration of VIP on SSL-induced responses. The purpose of these studies was to determine the duration of VIP-on-SSL attenuation of phenylephrine-and ANG II-induced vasoconstriction. The experimental design was similar to that outlined above, except that phenylephrine (0.1 µM) or ANG II (0.1 nM) was now suffused 30, 45, or 60 min after suffusion of VIP on SSL (0.1 nmol for 7 min) was stopped. Arteriolar diameter was determined during each intervention.
Mechanisms of responses evoked by VIP on SSL.
To begin to probe the mechanisms by which VIP on SSL attenuates phenylephrine-and ANG II-induced vasoconstriction in the cheek pouch, we determined the role of vasodilator prostaglandins and intracellular effector systems in mediating this response.
Role of prostaglandins. The purpose of these studies was to determine whether attenuation of vasoconstriction by VIP on SSL is mediated, in part, by local production of vasodilator prostaglandins, because VIP has been previously shown to elaborate these mediators (15, 17) . After the equilibration period, phenylephrine (0.1 µM) or ANG II (0.1 nM) was suffused on the cheek pouch for 7 min. Thirty minutes after suffusion of phenylephrine or ANG II was stopped and arteriolar diameter returned to baseline, indomethacin (10 mg/kg) was infused intravenously over a 30-min period using an infusion pump (Sage Instruments; final volume 1 ml), and suffusion of phenylephrine or ANG II was repeated. In another series of experiments, phenylephrine (0.1 µM) or ANG II (0.1 nM) was suffused for 7 min. Once suffusion of phenylephrine or ANG II was stopped and arteriolar diameter returned to baseline, indomethacin (10 mg/kg) was infused intravenously, then VIP on SSL (0.1 nmol) was suffused for 7 min. Thirty minutes thereafter, suffusion of phenylephrine or ANG II was repeated. Arteriolar diameter was determined during each intervention. In preliminary studies, we determined that intravenous infusion of indomethacin (10 mg/kg) for 30 min has no significant effects on arteriolar diameter. The concentration of indomethacin used in these studies has been previously shown to inhibit cyclooxygenase-and arachidonic acid-induced vasodilation in the cheek pouch (28) (29) (30) .
Role of NO-, cGMP-, and cAMP-dependent intracellular effector pathways. The purpose of these studies was to determine whether NO-, cGMP-, or cAMP-dependent intracellular signal transduction pathways that mediate VIP vasorelaxation in the cheek pouch and other vascular beds are involved in attenuation of phenylephrine-and ANG II-induced vasoconstriction by VIP on SSL (2, 10, 15, 16, 32) . To accomplish this goal, we determined whether other vasodilators that activate NO-, cGMP-, and cAMP-dependent intracellular signal transduction pathways in the peripheral microcirculation also attenuate phenylephrine-and ANG II-induced vasoconstriction (7, 9, 15, 18, 19, 30, (32) (33) (34) (35) (36) (37) (38) . The experimental design was similar to that outlined above, except that phenylephrine (0.1 µM) or ANG II (0.1 nM) was suffused for 7 min before and 30 min after suffusion of ACh (1.0 µM), an endothelium-and NO-dependent vasodilator; nitroglycerin (0.1 µM), an endothelium-independent, NO-dependent vasodilator; calcium ionophore A-23187 (1.0 µM), a receptor-independent, endothelium-and NO-dependent vasodilator; 8-bromo-cGMP (8-BrcGMP, 20 µM), a receptor-, endothelium-, and NOindependent vasodilator; or isoproterenol (0.01 µM), an endothelium-independent, cAMP-dependent vasodilator for 7 min each. Arteriolar diameter was determined during each intervention. In preliminary studies, we determined that the magnitude of vasodilation elicited by the vasodilators at concentrations used in these studies is similar to that elicited by VIP (1.0 nmol) and VIP on SSL (0.1 nmol).
Drugs. Egg yolk phosphatidylcholine, egg yolk phosphatidylglycerol, cholesterol, trehalose, indomethacin, ACh, isoproterenol, calcium ionophore A-23187 hemimagnesium salt, and 8-BrcGMP were purchased form Sigma Chemical (St. Louis, MO). Human VIP was purchased from American Peptide (Sunnyvale, CA). Nitroglycerin was purchased from American Reagent Laboratories (Shirley, NY). Indomethacin was dissolved in sodium bicarbonate. All drugs were diluted in saline to the desired concentrations on the day of the experiment.
Data and statistical analyses. When a compound was suffused on the cheek pouch, we determined the maximal change in arteriolar diameter and used it as the response to that compound in each animal. Arteriolar diameter was expressed as the ratio of experimental to control diameter, with control diameter normalized to 100%, to account for intra-and interanimal variability. Values are means Ϯ SE, except for the size of VIP on SSL and body weight, which are means Ϯ SD, because these data are not used for comparison between experimental groups. Statistical analysis was performed on actual values using repeated-measures ANOVA with Newman-Keuls multiple-range post hoc test to detect values that were different from control values. P Ͻ 0.05 was considered significant; n is the number of experiments, with each experiment representing a separate animal.
RESULTS
Mean arterial pressure was 97 Ϯ 2 mmHg at the start and 96 Ϯ 1 mmHg at the conclusion of the experiments (n ϭ 46, P Ͼ 0.5).
Effects of a VIP Receptor Antagonist on Vasoconstriction
Suffusion of phenylephrine and ANG II elicits a significant, concentration-dependent decrease in arteriolar diameter from baseline ( Figs. 1-3 ; n ϭ 4/group, P Ͻ 0.05). Moreover, phenylephrine (0.01 µM)-and ANG II (0.01 nM)-induced vasoconstriction is significantly potentiated by VIP-(10-28) (10.0 nmol; Fig. 1 ; n ϭ 4/group, P Ͻ 0.05). Arteriolar diameter decreased by 8.1 Ϯ 0.8 and 8.7 Ϯ 1.1% from baseline during suffusion of phenylephrine (0.01 µM) and ANG II (0.01 nM) alone, respectively, and by 14.1 Ϯ 0.9 and 13.2 Ϯ 0.6% from baseline during suffusion of phenylephrine (0.01 µM) and ANG II (0.01 nM) with VIP-(10-28) (10.0 nmol), respectively ( Fig. 1 ; P Ͻ 0.05). Suffusion of VIP-(1-12) (10.0 nmol) had no significant effects on phenylephrine-and ANG II-induced responses ( Fig. 1 ; n ϭ 4/group, P Ͼ 0.5).
Effects of VIP on Vasoconstriction
Suffusion of aqueous VIP (1.0 nmol) and VIP on SSL (0.1 and 1.0 nmol) elicits a significant increase in arteriolar diameter from baseline (23.7 Ϯ 1.2, 25.6 Ϯ 0.6, and 39.6 Ϯ 1.4%, respectively, n ϭ 4/group, P Ͻ 0.05). Suffusion of empty SSL has no significant effects on arteriolar diameter (n ϭ 4, P Ͼ 0.5). Vasoconstriction elicited by phenylephrine (0.1 µM) and ANG II (0.1 nM) was similar before (15.5 Ϯ 0.6 and 15.5 Ϯ 1.0% decrease from baseline, respectively) and after (15.6 Ϯ 1.7 and 14.5 Ϯ 0.7% decrease from baseline, respec- Fig. 2A ; n ϭ 4/group, P Ͼ 0.5). By contrast, suffusion of VIP on SSL (0.1 nmol) significantly attenuates phenylephrine-and ANG II-induced vasoconstriction in a concentrationdependent fashion ( Fig. 3 ; n ϭ 4/group, P Ͻ 0.05).
Arteriolar diameter decreased by 15.8 Ϯ 0.7 and 16.2 Ϯ 0.6% from baseline during suffusion of phenylephrine (0.1 µM) and ANG II (0.1 nM) before and by 6.7 Ϯ 1.3 and 6.2 Ϯ 0.2% after suffusion of VIP on SSL (0.1 nmol), respectively ( Fig. 3 ; n ϭ 4/group, P Ͻ 0.05). Empty SSL Fig. 3 ; n ϭ 4/group, P Ͼ 0.5).
Duration of VIP on SSL-Induced Responses
Attenuation of phenylephrine (0.1 µM)-and ANG II (0.1 nM)-induced vasoconstriction by VIP on SSL (0.1 nmol) was related to the time interval between conclusion of VIP-on-SSL suffusion and subsequent suffusions of both vasoconstrictors. Maximal attenuation was observed within 30 min and was no longer present 60 min after suffusion of VIP on SSL (0.1 nmol) was stopped ( Fig. 4 ; n ϭ 4/group, except for initial response groups to phenylephrine and ANG II, where n ϭ 12). (Table 1 ; n ϭ 4/group, P Ͼ 0.5).
Mechanisms of Responses
DISCUSSION
There are two new findings of this study. First, we found that VIP-(10-28), a VIP receptor antagonist Second, suffusion of aqueous VIP, which assumes a predominantly random coil conformation (11, 27) , has no significant effects on phenylephrine-and ANG IIinduced vasoconstriction. By contrast, association of VIP with SSL, which alters peptide conformation to a predominantly ␣-helix (11, 27) , elicits significant and reversible attenuation of phenylephrine-and ANG IIinduced responses. Maximal effect is observed within 30 min and is no longer seen after 60 min. These effects are not mediated by the phospholipid moiety of SSL, because empty SSL are inactive.
The concentration of VIP in the in situ cheek pouch microcirculation during suffusion of aqueous VIP and VIP on SSL was not determined in this study. However, it is not feasible to determine VIP concentration directly in the vicinity of in situ cheek pouch arterioles during suffusion of VIP on SSL, because the peptide remains associated with liposomes for a relatively prolonged period of time (8, 11, 26, 27, 31) . Rather, isolated cheek pouch arterioles exposed to aqueous VIP and VIP on SSL in the absence and presence of a detergent to dissolve SSL would have to be used to address this issue (27, 31, 32, 39) .
The hamster cheek pouch is an established model to study regulation of vasomotor tone in the peripheral microcirculation under normal and pathophysiological conditions (7, 18, 21, 22, 25, (27) (28) (29) (30) (31) (32) (33) (34) (35) . Xia et al. (39) showed that phenylephrine and KCl, two potent vasoconstrictors, elicit similar transient local and conducted depolarization in smooth muscle and endothelium of isolated cheek pouch arterioles. Importantly, Suzuki et al. (35) showed that VIP-induced vasodilation is blunted in the in situ cheek pouch of hamsters with spontaneous hypertension relative to normotensive hamsters. Partitioning of VIP into phospholipids amplifies and restores VIP vasorelaxation relative to aqueous VIP in the in situ cheek pouch of normotensive and spontaneously hypertensive hamsters, respectively (11, 26, 27, 32, 35, 36) . By contrast, Myers et al. (25) showed that ANG II-induced vasoconstriction is amplified in the cheek pouch of hamsters with experimentally induced renovascular hypertension. These data, coupled with the results of this study, suggest that VIP regulation of vasomotor tone during phenylephrine-and ANG II-induced vasoconstriction is dependent, in part, on secondary structure of the peptide. Further studies are warranted to determine the role of ␣-helix VIP in modulating vasoconstriction elicited by other agonists.
The mechanisms underlying the salutary effects of VIP on SSL in the cheek pouch were not identified in this study. Nonetheless, they are not related to local elaboration of vasodilator prostaglandins, because indomethacin, at a concentration that inhibits cyclooxygenase-and arachidonic acid-induced vasodilation in the cheek pouch (28) (29) (30) , has no significant effects on attenuation of phenylephrine-and ANG II-induced vasoconstriction by VIP on SSL (17) . In addition, the effects of VIP on SSL are not mediated by NO-, cGMP-, or cAMP-dependent intracellular effector mechanisms in the peripheral microcirculation, because selected vasodilators that activate these pathways have no significant effects on phenylephrine-and ANG IIinduced vasoconstriction.
On balance, these data suggest that ␣-helix VIP opposes ␣-adrenergic-and ANG II-induced vasoconstriction in the in situ peripheral microcirculation by activating a specific plasma membrane-dependent process(es) rather than by eliciting vasodilation that overwhelms vasoconstriction or by nonspecific effects on vascular smooth muscle contractility (13, 18, 20, 26) . Clearly, additional studies using isolated microvascular smooth muscle cells and plasma membranes are indicated to characterize this process(es).
Perspectives
This study suggests that ␣-adrenergic-and ANG II-dependent metabolic pathways interact with VIP to regulate vasomotor tone in the in situ peripheral microcirculation. This process may be related, in part, to vasoconstriction-induced release of VIP from nerve endings. The peptide thus released may interact with plasma membrane phospholipids in target cells, change its conformation from predominantly random coil in interstitial fluid to ␣-helix in phospholipid bilayer, and activate a specific plasma membrane-dependent process(es) that promotes vasoconstrictolysis.
In summary, the results of this study suggest that vasoconstriction modulates VIP release from nerve endings in the in situ hamster cheek pouch. They indicate that ␣-helix VIP, the optimal conformation for ligand-receptor interaction (3, 16, 26, 32) , opposes ␣-adrenergic-and ANG II-induced vasoconstriction in this organ in a reversible, prostaglandin-, NO-, cGMP-, and cAMP-independent fashion. Values are means Ϯ SE expressed as percent change from baseline arteriolar diameter; n ϭ 4/group. Each vasodilator was suffused for 7 min. Before, maximal vasoconstriction before suffusion of phenylephrine or ANG II for 7 min; after, maximal vasoconstriction 30 min after suffusion of phenylephrine or ANG II was stopped; 8-BrcGMP, 8-bromo-cGMP.
